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Abstract: Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells (HSCs) is widely used for
evaluation of graft adequacy of peripheral blood and bone marrow stem cell grafts. In the present study, we review and compare
the major counting techniques of stem and progenitor cells. The methods are: the Milan/Mullhouse protocol, two-platform
ISHAGE (International Society of Hematotherapy and Graft Engineering) and single-platform ISHAGE analysis system.
According to the Milan/Mulhouse protocol, HSCs are identified by CD34 antibody staining and easy gating strategy. The
ISHAGE guidelines for detection of CD34+ cells are based on a four-parameter flow cytometry method (CD34PE/CD45PerCP
staining, side and forward angle light scatter) thus employing multiparameter gating strategy. With two-platform ISHAGE
protocol, an absolute CD34+ count is generated by incorporating the leukocyte count from an automated hematology analyser.
The single-platform ISHAGE method to determine the absolute CD34+ count directly from a flow cytometer includes the use
of Trucount tubes (Becton Dickinson) with a known number of fluorescent beads. CD34+ cells were quantified in mobilized
peripheral blood, collected by leukapheresis, and bone marrow from 42 samples from patients with hematological malignancies.
The differences against the means display low disagreement between the Milan/Mulhouse and ISHAGE protocols, with
discrepancies of up to 2.5% (two-platform ISHAGE) - 2.6% (single-platform ISHAGE) in enumeration of CD34+ cells in
leukapheresis product and 4.8% (two-platform ISHAGE) - 4.9% (single-platform ISHAGE) in bone marrow. Our results show
high correlation among all three methods. Since the three protocols are compatible, choosing the most convenient in terms of
costs, simplicity and compliance with clinical results appears to be a logical consequence. (www.cm-uj.krakow.pl/FHC)
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Introduction
Hematopoietic stem and progenitor cells (HSCs) ob-
tained either from bone marrow (BM) or mobilized
peripheral blood (PB) are used for autologous transplan-
tation following high-dose chemotherapy in patients
with hematological malignancies [4, 11, 12] . These cells
are characterized by the expression of the adhesion
receptor CD34 [13, 22, 23, 25]. The clinical value of
determination of the accurate absolute numbers of
CD34+ cells is the most important parameter for evalu-
ating stem and progenitor cell content in hematopoietic
transplantation [6, 7, 9].
In this regard, several assays for CD34+ cell enumer-
ation have been proposed, but lack of standardized pro-
cedures has resulted in the generation of divergent data
[15-18, 20, 24]. The first attempt at enumerating CD34+
progenitors by flow cytometry was Milan/Mulhouse
protocol based on the evaluation of CD34+ cells with a
low light scatter (SSC), after initial forward vs SSC live
gating excluding debris, platelets, erythrocytes and cell
aggregates [5,17]. This protocol is based on two-plat-
form method, whereby the percentage of CD34+ cells is
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determined by flow cytometry and leukocyte count by
an automated hematology analyzer. 
Most laboratories propose the second two-platform
method - ISHAGE protocol published by the Interna-
tional Society of Haematotherapy and Graft Engineer-
ing, designed as a set of guidelines for the accurate
detection of CD34+ cells based on four-parameter flow
cytometry method (CD45PerCP/CD34 PE staining, side
and forward angle light scatter) [19, 20]. Importantly,
this approach allows the discrimination of HSCs (which
express relatively low levels of CD45 on their surface)
from lymphocytes and monocytes, and thus allowing the
verification of "true" CD34+ cells as being dim for CD45
fluorescence and having low side scatter (CD45dim,
SSClow) [19, 21].
The development of single-platform methods enable
the absolute CD34+ cell count to be determined by a
single instrument - flow cytometer [2, 5]. The flow
cytometry based on single-platform method concen-
trates on incorporation of a known number of fluorescent
beads into the sample. Using a lyse-no-wash procedure
for sample preparation enables the ratio of CD34+ cells
to beads to be determined and the absolute CD34+ cells
count to be calculated. One of them is the single-plat-
form ISHAGE [3, 10]. This new protocol combines the
advantages of Trucount tubes and the ISHAGE gating
strategy.
In the present study, we compare all three protocols:
two-platform protocols (ISHAGE and Milan/Mulhouse)
and single-platform ISHAGE protocol with each other.
Materials and methods
Cell sources. Bone marrow (BM) and leukapheresis product (LKP)
samples were collected from 42 patients with hematological malig-
nancies. BM aspirates (n=10) were harvested from patients in steady-
state hematopoiesis undergoing general anesthesia for routine
surgical procedures. LKP samples (n=32) were collected following
chemotherapy and mobilization with subcutaneous granulocyte col-
ony-stimulating factor (G-CSF, filgrastim) at 10 μg/kg per day. The
leukaphereses were initiated when the number of CD34+ cells was
≥20×106/l and performed as an outpatient procedure on a Fenwal
CS-3000 Plus (Baxter) separator with a continuous flow of blood
cells following the manufacturer’s instruction for mononuclear cell
collection. 
Monoclonal antibodies (MoAbs). The following mouse-derived
antibodies were used in this study: phycoerytrin (PE)- conjugated
8G12 (HPCA-2), peridinin-chlorophyll-protein (PerCP)-conjugated
CD45 (2D1), PE-IgG1 isotype control; antibodies were purchased
from Becton Dickinson (BD).
Cell preparation and immunofluorescence staining. For each
patient’s sample, five tubes were prepared and processed in parallel:
(1) single staining with CD34 PE were added to the wash tube; (2)
double staining with CD34 PE and CD45 PerCP - wash tube; (3)
double staining with CD34 PE and CD45 PerCP - Trucount tube; (4)
isotype control reagent-IgG1 PE and CD45 PerCP - wash tube and
(5) isotype control reagent-IgG1 PE and CD45 PerCP - Trucount
tube. When necessary, the samples were diluted to adjust the leuko-
cyte count to 10×109/l and 100 μl aliquots were placed onto the
bottom of the tubes. To block binding of Fc receptors and avoid to
nonspecific staining, the cells were subsequently incubated with 10%
(vol/vol) heat-inactivated human AB serum at 4˚C. Tubes were
stained and prepared according to the manufacturer’s recommenda-
tion. In case of single-platform method (lyse/no wash) cells were not
washed (tubes no. 3 and no. 5). All samples were then stored at 4˚C
in the dark and analysed by flow cytometry within 1 h.
Hematological cell counts. The total number of CD34+ cells from
BM and LKP samples were measured by an automatic cell counter,
the Sysmex F820 (TOA Medical Electronics Kobe, Japan) or by
direct flow cytometer (Trucount BD). In case of two-platform meth-
ods, the results were expressed as %CD34+ cells, and the absolute
CD34+ cells/μl calculated as %CD34+ cells × WBC×103μl. In case
of single-platform method, the number of CD34+ cells per microliter
was calculated according to the following formula: 
                            No. of CD34+ cells ×  bead count per test × dilution factorCD34+ cells/μl = --------------------------------------------------------------------------------------------------------------------------------------------------
                                                No. of beads collected
Sample acquisition. Cells were acquired on three-color FACS Cali-
bur flow cytometer (BD) equipped with a 488 nm argon laser and
analyzed with CellQuest 3.1 software. The instrument was aligned
Fig. 1. Milan/Mulhouse gating strategy on a leukapheresis sample.
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and calibrated daily using a three-color mixture of CaliBRITE beads
(BD) with FACSComp software (BD). In order to comply with
statistical requirements, 50 000 events were acquired for each sample
in Milan/Mulhouse protocol. In the event of ISHAGE (single- and
two-platform) a total of 100 000 leukocytes (G1), and in case of
single-platform ISHAGE 2 000 bead events were collected. 
Gating strategy: Milan/Mulhouse protocol. According to the
Milan/Mulhouse protocol, nucleated cells were identified and distin-
guished from platelets, unlysed erythrocytes, and debris by their
higher FSC signals (R1 in Fig. 1, Plot 1). The FL vs. SSC plot of the
isotype control mAb-stained sample was then used to set the marker
discriminating between positive and negative FL signals (R2 in Fig.
1, Plot 2). Using this marker, HCSs were identified as CD34+SSClow
in the CD34 mAb-stained sample (R2 in Fig. 1, Plot 3). Finally, the
events in R2 of the isotype control (Fig. 1, Plot 2) were subtracted
from the number of CD34+ events (Fig. 1, Plot 3). The basis was
nucleated cells (as based on FSC and SSC criteria) and absolute
counts were derived from a separate leukocyte count on a hemato-
logy analyzer. 
Gating strategy: two-platform ISHAGE protocol. For ISHAGE
analysis, a region R1 (Fig. 2 and Fig. 3, Plot 1) representing CD45+
events was established to include all nucleated WBCs. Red blood
cells, nucleated red blood cells, platelets, and other cellular debris
are excluded from this region since they do not express CD45
structures. CD45+ events in the region R1 were then analyzed for
CD34 staining, and positive events were gated into R2 (Fig. 2 and
Fig. 3, Plot 2). Events defined by regions R1 and R2 were analyzed
on dot-plot describing granularity vs. CD45 staining. Into the region
R3 were gated events representing true blast cells, which were
identified as SSClow, CD45dim (Fig. 2 and Fig. 3, Plot 3). Events into
region R4 were defined as cells with characteristics of blast cells and
lymphocytes. Cells from region R4 were named true CD34+ blast
cells (Fig. 2 and Fig. 3, Plot 4). The region R5 contained lymphocytes
(CD45bright, SSClow) (Fig. 2 and Fig. 3, Plot 5). 
Gating strategy: single-platform ISHAGE protocol. Figure 4
shows the gating strategy for CD34 analysis using Trucount tubes.
Since Trucount beads produce a very low forward scatter signal, a
forward scatter threshold cannot be used. A FL3 threshold was set
on CD45 expression, with care to ensure that CD45low/ CD34+ cells
were not excluded from the analysis (Fig. 4, Plot 1). The Trucount
beads, evident as a population of bright events in each fluorescence
channel, were enumerated in region R6 and R7 (Fig. 4, Plot 5 and
Plot 7). To exclude nonbead events, R6 was drawn tightly around the
beads in line with the manufacturer’s instruction. CD34+ events were
enumerated in G4 (Fig. 4, Plot 4). 
Fig. 2. Two-platform ISHAGE strategy on a leukapheresis sample. 1: Sample stained with anti-CD45 PerCP. 2: Anti-CD34 PE staining of
cells in region R1. Region R2 represents CD34+ cells. 3: CD45 vs. side-scatter analysis of CD34+ cells gated by R1 and R2. 4: Region R4
represents a blast/lymphocyte region (cells gated by R1, R2 and R3). 5: CD45 vs. CD34 analysis of all events. 6: Region R5 - lymphocytes.
7: CD34+ cells enumerated only by gating the positive cells in region R1. 8: CD45 vs. side-scatter analysis of events gated in region R1. 
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Evaluation of linearity and reproducibility. For the linearity assay,
serial dilutions were prepared, starting from 1000, 500, 150, 50
CD34+ cells/μl and quantified by the three different methods. Preci-
sion of the absolute counting method was measured at three target
points. Samples with approximately 1000, 150, and 50 CD34+
cells/μl were processed two times for each method.
Statistical analysis. The results obtained by each of the three meth-
ods were compared using the Wilcoxon matched pairs test for
nonparametrically distributed data, and linearity regression analysis,
using Statistica software. Agreement between the methods was
assessed by analysis of the relationship between the differences and
the mean of the differences as recommended by Bland and Altman
(MedCalc statistical software). Coefficients of variation (CV) were
calculated according to the following formula:
[standard deviation (SD)/mean] × 100(%) 
Results
The analysis of the 42 samples tested showed no signi-
ficant differences for the results obtained by the
Milan/Mulhouse protocol in comparison to single-plat-
form ISHAGE and two-platform ISHAGE methods.
Linear regression analysis for Milan/Mulhouse vs. ISH-
AGE two-platform and vs. ISHAGE single-platform
gave respectively r = 0.96 and r = 0.95 (Table 1).
Statistical analysis of CD34+ population demonstrated
that results obtained by single-platform ISHAGE assay
showed the highest correlation with the two-platform
ISHAGE assay, giving r = 0.98. The Wilcoxon signed
rank test showed that there was no statistically signifi-
cant difference between the three methods (p > 0.05). 
Reproducibility was tested by replicate measure-
ments of samples with known CD34+ cell concentra-
tions, and results were expressed as a coefficient of
variation (CV) (Table 2). For the lowest sample concen-
tration of 50 CD34+cells/μl, CV values were the highest,
being 12.2% for the Milan/Mulhouse, 4.3% for the two-
platform ISHAGE and 4.0% for the single-platform
ISHAGE assays. For higher cells concentration (150 and
1000 CD34+cells/μl), CV values for single-platform
assay were similar to those for the two-platform assays,
proving comparable precision of the three methods
(Table 2). Finally, in order to further explore whether
the methods differ from each other, we used a statistical
approach aimed at assessing the degree of compatibility.
Fig. 3. Analysis of CD34+ cells in BM. Analysis was performed exactly as described for the LKP sample in Figure 2.
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Our results (Fig. 5) showed a graphical representation of
differences between the tested methods against their
mean, to take into consideration the sources of HSCs.
Bland-Altman plot (Fig. 5) revealed the majority of data
points distributed around the mean of the three methods.
In line with the results of regression analysis, the meth-
ods are indeed comparable since considerable discrep-
ancies do not exist and degree of compatibility is
acceptable (disagreement = 2.5% in Milan/Mulhouse vs.
ISHAGE two-platform protocol, 2.6% in Milan/Mul-
house vs. ISHAGE single-platform in case of LKP, and
disagreement = 4.8% in Milan/Mulhouse vs. ISHAGE
two-platform protocol and 4.9% in Milan/Mulhouse vs.
ISHAGE single-platform protocol in case of BM). How-
ever, using the ISHAGE analysis, the CD34+ cells from
bone marrow in region R2 exhibited a more heteroge-
neous staining pattern than that of the leukapheresis
sample (Fig. 3 Plot 7 and Fig. 2 Plot 7). Additionally,
these BM CD34+ cells showed a greater range of granu-
larity when analyzed on a dot-plot describing CD45
fluorescence vs. side scatter (Fig. 3 Plot 3, region R3).
In such case, where the bone marrow may be enriched
with primitive cell types (as a consequence of post-che-
motherapy bone marrow regeneration), it might be more
useful to enumerate CD34+ cells in the R3 region rather
than in the R4 region.
Discussion
Flow cytometric enumeration of CD34+ cells has
become widely accepted as the technique of choice to
quantify HSCs for the clinical management of stem cell
transplantation [8, 15, 20].
Despite the establishment of guidelines for CD34+
cell enumeration by two-platform flow cytometric
assay, standardization of results has been difficult to
achieve [14, 15, 19, 20]. 
In order to contribute to this issue we have compared
three different methods of CD34+ cell enumeration: the
Milan/Mulhouse protocol, the two-platform ISHAGE
protocol and single-platform ISHAGE protocol with the
aim of verifying the differences between them, espe-
cially in terms of clinical impact. 
The new simplified single-platform assay should
avoid some sources of the probable errors involved in
the two-platform assay, namely the washing step after
Fig. 4. Single-platform ISHAGE gating strategy using
Trucount tubes in LKP.
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staining and the use of the white blood cell count for
calculation of CD34+ cell concentration. Adding a
known number of fluorescent beads to the single-plat-
form ISHAGE protocol allows the determination of
absolute CD34 counts without the added variable of
hematology analyzer. In fact, this method has the ad-
vantage of being rapid and straightforward. This advant-
age of single-platform assay offers the possibility of
higher level of standardization between laboratories.
However, comparison of the two-platform ISHAGE
protocol with the single-platform ISHAGE protocol
showed a high degree of concordance over a wide range
Table 1. Regression analysis between the three methods
Methods N R P-value
Milan-Mulhouse / 
ISHAGE two-platform 42 0.96 <0.001
Milan-Mulhouse / 
ISHAGE single-platform 42 0.95 <0.001
ISHAGE two- / 
ISHAGE single-platform 42 0.98 <0.001
Table 2. Reproducibility of the same sample tested four times
Sample
concentration
(CD34+
cells/μl)
Coefficient of variation (%)
Milan/
Mulhouse
ISHAGE 
two-platform
ISHAGE
single-platform
  50 12.2 4.3 4.0
 150  6.4 3.6 3.2
1000  3.1 2.9 2.6
Fig. 5. Bland-Altman plot displaying differences of methods against their mean. A: Milan/Mulhouse vs. two-platform ISHAGE in LKP. B:
Milan/Mulhouse vs. single-platform ISHAGE in LKP. C: Milan/Mulhouse vs. two-platform ISHAGE in BM. D: Milan/Mulhouse vs.
single-platform ISHAGE in BM. Solid line represents the mean of differences or bias. Dashed lines represent mean of the difference (bias)
± 2 SD. A mean bias equal to zero represents perfect agreement.
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of CD34 counts (correlation coefficient r = 0.98). Our
results are consistent with those of Keeney et al. [10],
but Brocklebank and Sparrow [1] reported significant
disagreement between the methods. However, the latter
study concerned cord blood. 
For each of the methods, linearity was observed, with
a good relationship between the results as demonstrated
by the high correlation coefficient (Table 2). The preci-
sion of the methods evaluated by replicate measure-
ments was reflected by low CV values for the all the
concentrations tested, with the exception of the
Milan/Mulhouse assay for the lowest concentration of
CD34+ cells (50/μl). These high CV values may be
associated with the detection level of this method and
gating strategy. 
In terms of gating strategy, in the Milan/Mulhouse
protocol the major contaminants appeared to be red
blood cells and their nucleated precursors, based on their
light-scattering characteristics (very low forward scatter
and low side scatter). Red blood cells, their nucleated
precursors, platelets and other cell debris than can inflate
the number of CD34+ events, and which are present in
highly variable numbers in clinical samples, are thereby
excluded. In case of the ISHAGE assays, lymphocytes
that exhibit characteristics of side and forward scatter
similar to that of true CD34+ blasts can now be separated
from CD34+ cells since they stain brightly for CD45.
Similarly, monocytes, which can partially overlap
blast/lymphocytes gates on light-scatter analysis, can be
distinguished by their high CD45 expression and in-
creased side scatter. 
Our results showed that the studied methods are
comparable and therefore interchangeable due to a very
low degree of disagreement. The value of disagreements
is higher for evaluation of CD34+ from bone marrow
than from leukapheresis product, when comparing the
Milan/Mulhouse protocol with the single-platform ISH-
AGE and two-platform ISHAGE protocol. Comparison
of CD34+ cells from leukapheresis product and bone
marrow showed that bone marrow CD34+ cells exhibited
a heterogeneous staining pattern as well as heteroge-
neous granularity.
In summary, comparison of the Milan/Mulhouse and
the single-platform ISHAGE techniques with our rou-
tine two-platform ISHAGE flow cytometric assay gave
high correlation. The new method, single platform ISH-
AGE, allows the direct determination of absolute num-
bers of CD34+ cells. However in our hands, comparison
of the two-platform ISHAGE protocol with modified
single-platform ISHAGE protocol showed high correla-
tion and compatibility. The sequential gating strategy of
the ISHAGE protocol requires more manual work as
compared to the Milan/Mulhouse protocol, but un-
doubtedly is a more sensitive and reproducible method
of enumerating CD34+ cells derived from bone marrow
and mobilized peripheral blood.
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